Evidence map›Paper›PMID 30223807›Full record

ArticleBMC complementary and alternative medicine2018

Yiqihuoxue decoction protects against post-myocardial infarction injury via activation of cardiomyocytes PGC-1α expression.

Fanghe Li, Shuwen Guo, Chunguo Wang, Xiaolou Huang, Hui Wang, Xiaobo Tan, Qian Cai, Jiani Wu, Yuqin Zhang, Xi Chen and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC complementary and alternative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Effects ofEvidence-based complementary and alternative medicine : eCAM · 2021
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Fanghe LiBeijing University of Chinese Medicine, Beijing, 100029, China.
Shuwen GuoBeijing University of Chinese Medicine, Beijing, 100029, China. guo1163@163.com.
Chunguo WangBeijing University of Chinese Medicine, Beijing, 100029, China.
Xiaolou HuangBeijing University of Chinese Medicine, Beijing, 100029, China.
Hui WangBeijing University of Chinese Medicine, Beijing, 100029, China.
Xiaobo TanBeijing University of Chinese Medicine, Beijing, 100029, China.
Qian CaiBeijing University of Chinese Medicine, Beijing, 100029, China.
Jiani WuBeijing University of Chinese Medicine, Beijing, 100029, China.
Yuqin ZhangBeijing University of Chinese Medicine, Beijing, 100029, China.
Xi ChenBeijing University of Chinese Medicine, Beijing, 100029, China.
Wangou LinBeijing University of Chinese Medicine, Beijing, 100029, China.
Binyue ZhangBeijing University of Chinese Medicine, Beijing, 100029, China.
Beijing University of Chinese Medicine · CN

Funding

National Natural Science Foundation of China 81473552
6 · The paper itself

Abstract

backgroundMitochondrial dysfunction has been implicated in the pathogenesis of ischemic heart disease, exacerbating cardiomyocytes injury in myocardial infarction (MI). Peroxisome proliferator-activated receptor gamma co-activator (PGC-1α) has been recognized as the key regulator of mitochondrial biogenesis and energy metabolism. Yiqihuoxue decoction (YQHX), a Traditional Chinese Medicine (TCM) prescription, can prevent and treat ischemic heart disease. However, the mechanisms of YQHX on PGC-1α expression in the ischemic heart have remained unclear.

methodsMyocardial ischemia rat model and ischemia/hypoxia injury model in the cardiomyocytes were used to minic human cardiovascular disease. Rats were randomly assigned into 4 groups: Sham, Model, YQHX (8.2 g/kg) and Trimetazidine (10 mg/kg) group. 28 days after MI, cardiac functions and morphology were detected by echocardiography and HE staining, respectively. In vitro, the effects of YQHX on H9c2 cell viability, LDH and ROS were detected, respectively. PGC-1α relevant proteins were evaluated by Western blotting.

resultsIn vivo, echocardiography and HE staining results showed that YQHX improved cardiac functions and modified pathological changes. YQHX enhanced PGC-1α expression and improved the mitochondrial ultrastructure and functions in rats MI model for 4 weeks. Further, we explored its potential mechanisms in cardiomyocytes. In vitro, YQHX significantly enhanced cell viability and reduced LDH release and ROS production induced by hypoxia in cardiomyocytes. Interestingly, exposure of cardiomyocytes to hypoxic conditions for 12 h induced the downregulation of PGC-1α expression, but the expression levels nearly returned to the normal state after hypoxia for 24 h. YQHX significantly enhanced PGC-1α expression between 12 h and 24 h induced by hypoxia through a mechanism associated with the activation of AMPK phosphorylation in H9c2 cells. In addition, YQHX upregulated the expression of Tfam and NRF-1, while NRF-1 expression was completely blocked by an AMPK inhibitor. YQHX largely restored the mitochondrial morphology and increased mitochondrial membrane potential in hypoxia-induced injury. Furthermore, the UHPLC-LTQ-Orbitrap-MS

conclusionsThese results suggest that the protective effect of YQHX on cardiomyocytes against hypoxia-induced injury may be attributed to activation of PGC-1α and maintenance of mitochondrial functions through a mechanism involving the activation of AMPK phosphorylation.

Indexed as

AnimalsCardiotonic AgentsCell LineDrugs, Chinese HerbalHeartMaleMyocardial InfarctionMyocardiumMyocytes, CardiacPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaRatsRats, Sprague-DawleyCardiotonic AgentsDrugs, Chinese HerbalPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPpargc1a protein, ratCardiomyocytesMyocardial ischemiaPGC-1αYiqihuoxue decoction (YQHX)

Identifiers

PMID30223807
PMCPMC6142634
OpenAlexW2889788611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.